 Connection
James Burton to Recombinant Proteins
This is a "connection" page, showing publications James Burton has written about Recombinant Proteins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.190 |
|
|
|
-
Burton JR, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014 Sep; 61(3):508-14.
Score: 0.091
-
Burton JR, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, Terrault N, Rosen HR. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol. 2008 Sep; 49(3):329-38.
Score: 0.061
-
Reiner JS, Lundergan CF, van den Brand M, Boland J, Thompson MA, Machecourt J, Py A, Pilcher GS, Fink CA, Burton JR, et al. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol. 1994 Nov 15; 24(6):1439-44.
Score: 0.024
-
Rosen HR, Weston SJ, Im K, Yang H, Burton JR, Erlich H, Klarquist J, Belle SH. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology. 2007 Aug; 46(2):350-8.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|